Lipigon Pharmaceuticals AB and Leaderna Therapeutics embarked on a strategic partnership to develop and commercialize Lipisense's drug candidate Lipisense, aimed at treating dyslipidemias such as severe hypertriglyceridemia (SHTG). This collaboration leverages the strengths of both companies to efficiently advance the clinical progress of Lipisense. Recently, Leaderna received approval to start a Phase I study in China.